AC Immune SA (NASDAQ:ACIU) has announced dosing of the first subject in a Phase 1 study of ACI-3024, an investigational oral small molecule Tau Morphomer inhibitor to address neurodegenerative diseases that are characterized by the presence of pathological Tau aggregates.
This is the first significant advancement in AC Immune’s collaboration with Eli Lilly and Company (NYSE:LLY).
The trial will assess safety, tolerability, pharmacokinetics, and pharmacodynamics of ACI-3024 in healthy volunteers.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.